Drug data last refreshed 11h ago · AI intelligence enriched 1w ago
MIOSTAT (carbachol) is a direct-acting cholinergic agonist administered intraocularly as a solution. It induces miosis (pupil constriction) and is used during ophthalmic surgery to achieve rapid pupillary constriction. The drug facilitates anterior chamber stability and iris sphincter muscle contraction during intraocular procedures.
Legacy product with approaching loss of exclusivity; limited team expansion expected as market matures.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Efficacy and Safety of BRIMOCHOL PF and CARBACHOL PF in Chinese Presbyopia Patients
Working on MIOSTAT offers experience managing a legacy surgical specialty product with stable but declining market dynamics. This role is best suited for professionals comfortable with mature-product stewardship, cost optimization, and preparation for generic transition rather than high-growth commercial expansion.
Worked on MIOSTAT at Alcon? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.